Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Valeant Pharmaceuticals International, Inc.
15 oktober, 2015
Levi & Korsinsky, LLP announces that it has commenced an investigation of Valeant Pharmaceuticals International, Inc. (“Valeant Pharmaceuticals” or the “Company”) (NYSE:VRX) concerning possible violations of federal securities laws by certain officers and directors.
On October 14, 2015, after the market closed, Valeant Pharmaceuticals issued a press release acknowledging the receipt of a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting materials related to the Company’s patient assistance programs, financial support for patients, distribution of its products, pricing decisions, and information the Company provided to the Centers for Medicare and Medicaid Services. The press release also acknowledged its receipt of, and response to, a letter from Senator Claire McCaskill concerning the Company’s products Nitropress and Isuprel. Upon this news, the share price of Valeant Pharmaceuticals fell as much as $22.06–or 12%–from its previous closing price of $177.29 during intraday trading on October 15, 2015 to trade at $155.23. To obtain additional information about the investigation, go to:
http://zlk.9nl.com/valeant-pharmaceuticals-vrx
or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151015006562/en/
Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Valeant Pharmaceuticals International, Inc.
15 oktober, 2015
Levi & Korsinsky, LLP announces that it has commenced an investigation of Valeant Pharmaceuticals International, Inc. (“Valeant Pharmaceuticals” or the “Company”) (NYSE:VRX) concerning possible violations of federal securities laws by certain officers and directors.
On October 14, 2015, after the market closed, Valeant Pharmaceuticals issued a press release acknowledging the receipt of a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting materials related to the Company’s patient assistance programs, financial support for patients, distribution of its products, pricing decisions, and information the Company provided to the Centers for Medicare and Medicaid Services. The press release also acknowledged its receipt of, and response to, a letter from Senator Claire McCaskill concerning the Company’s products Nitropress and Isuprel. Upon this news, the share price of Valeant Pharmaceuticals fell as much as $22.06–or 12%–from its previous closing price of $177.29 during intraday trading on October 15, 2015 to trade at $155.23. To obtain additional information about the investigation, go to:
http://zlk.9nl.com/valeant-pharmaceuticals-vrx
or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151015006562/en/
Nibe
Evolution
Nibe
Evolution
Marknadsöversikt
1 DAG %
Senast
1 mån
